Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esreboxetine Maintenance Study in Fibromyalgia
NCT00796601Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of esreboxetine in fibromyalgia (FM), sponsored by Pfizer. Planned start May 2009; status: withdrawn.
02
Drugs
esreboxetine
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT00796601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796601.